Assignee
REGENERX BIOPHARMACEUTICALS
US·1 granted patent·19 pending applications·3 citations·filing 2003–2015
Top patents by PatentIndex Score
20 records- 0176US8383576B2LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilizedREGENERX BIOPHARMACEUTICALS·Filed 2006·Granted Feb 26, 2013·3 cites·6 claims
- 0257US2011172155A1Beta thymosin fragmentsREGENERX BIOPHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 0356US2011144020A1Treatment of infections and other disordersREGENERX BIOPHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 0456US2010204147A1Methods For Delivering Thymosin Beta 4, Analogues, Isoforms and Other DerivativesREGENERX BIOPHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 0554US2008096817A1METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVESREGENERX BIOPHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 0649US2011124550A1Thymosin beta 4 promotes wound repairREGENERX BIOPHARMACEUTICALS·Filed 2010·Application pending·0 cites
- 0749US2006263360A1Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivativesREGENERX BIOPHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 0848US2013196912A1Beta thymosin fragmentsREGENERX BIOPHARMACEUTICALS·Filed 2013·Application pending·0 cites
- 0948US2008051348A1Treatment of infections and other disordersREGENERX BIOPHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 1047US2008248993A1Modified Beta Thymosin PeptidesREGENERX BIOPHARMACEUTICALS·Filed 2006·Application pending·0 cites
- 1146US2007015698A1Treatment of skin, and wound repair, with thymosin beta 4REGENERX BIOPHARMACEUTICALS·Filed 2005·Application pending·0 cites
- 1245US2006089310A1Treatment of infections and other disordersREGENERX BIOPHARMACEUTICALS·Filed 2003·Application pending·0 cites
- 1344US2009053194A1Method of treating or preventing biological or immunological responses to a reactive chemical or biological or toxic agentREGENERX BIOPHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1443US2009214507A1Method of treating preventing, inhibiting or reducing damage to cardiac tissueREGENERX BIOPHARMACEUTICALS·Filed 2005·Application pending·0 cites
- 1542US2004170625A1Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivativesREGENERX BIOPHARMACEUTICALS·Filed 2003·Application pending·0 cites
- 1642US2006246057A1Treatment or prevention of damage due to radiation exposureREGENERX BIOPHARMACEUTICALS·Filed 2004·Application pending·0 cites
- 1740US2015203561A1Beta thymosin fragmentsREGENERX BIOPHARMACEUTICALS·Filed 2015·Application pending·0 cites
- 1840US2009169538A1Methods of Treating or Preventing Tissue Damage Caused by Increased Blood FlowREGENERX BIOPHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 1938US2010278934A1Methods and compositions for conserving and/or preparing an organ or tissue for transplantREGENERX BIOPHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 2036US2011020449A1Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tb4), analogues, isoforms and other derivativesREGENERX BIOPHARMACEUTICALS·Filed 2010·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →